We stratified EGFR mutant patients by median RBM10 mRNA expression and found that patients whose tumors expressed lower levels of RBM10 progressed earlier on EGFR TKI therapy (PFS: RBM10 low = 11.6 months, RBM10 high = 16.7 months, Wilcoxon test p-value = 0.03)...Decreased PFS in the RBM10 low cohort was associated with decreased initial tumor response rates...